IASbhai Editorial Hunt
To be the best, you must be able to handle the worst.-Wilson Kanadi
EDITORIAL 21:“Regional bonding”
SOURCES: THE HINDU EDITORIAL/EDITORIALS FOR UPSC CSE MAINS 2020
India needs to engage with its neighbors for the realisation of its global ambitions
SYLLABUS COVERED: GS 2:3:International Relations:Trade
Integrating South east Asia is a dubious challenge for Asian economies. Comment -(GS 3)
Author has refered to former Sri Lankan Prime Minister Ranil Wickremesinghe’s speech at a conclave last week and justified a prompt role of what economies can do for a better integration tomoorrow !
India-Pakistan tensions are bringing economic integration within the SAARC region to a “standstill”, explaining that the original purpose of the South Asian group was to build a platform where bilateral issues could be set aside in the interest of regional growth.
Decrying the lack of economic integration in South Asia, and the failure of SAARC, as well as BIMSTEC (which includes Bangladesh, Bhutan, India, Myanmar, Nepal, Sri Lanka and Thailand), to engender more intra-regional trade.
An even smaller sub-grouping of four countries with complementary economies: India, Sri Lanka, Bangladesh and Thailand, to begin the process of reducing tariffs and demolishing non-tariff barrier regimes.
When it comes to the intra-regional share of total trade, SAARC and BIMSTEC languish behind groupings such as ASEAN, EU and MERCOSUR.
The Sri Lankan leader also suggested that with India’s leadership, a more integrated South Asian region would be better equipped to negotiate for better terms with RCEP so as not to be cut out of the “productivity network” in Asia, and envisioned an Economic Integration Road Map to speed up the process.
The government has made it clear that talks with Pakistan are strictly off the table, and that a SAARC summit, which has not been held since 2014, is unlikely to be convened anytime soon.
Second, the government, which has taken a protectionist turn on multilateral trade pacts, is relying more on direct bilateral deals with countries rather than overarching ones that might expose Indian markets to flooding by Chinese goods.
However, the overall projection that India’s global reach will be severely constrained unless it is integrated with its neighbours, and tensions with Pakistan are resolved, cannot be refuted(disprove).
India needs to be more accommodative for the realisation of its ambitions.
EDITORIAL 22:“State lethargy amidst cough syrup poisoning“
SOURCES: THE HINDU EDITORIAL/EDITORIALS FOR UPSC CSE MAINS 2020
The writer is a public health activist and was the whistleblower in the Ranbaxy case
State lethargy amidst cough syrup poisoning
A national recall of Coldbest-PC, the medicine behind the death of 12 children in Jammu, is needed
SYLLABUS COVERED: GS 3:Pharma Industry:DCGI
Mass glycol poisoning event in India has raised the alarm for drug sellers as well as practitioners. Evaluate and provide your opinion on how to tackle such drug menace. -(GS 3)
This is a beautiful article explaining why and how recalling a drug in India is so difficult. Author initiates the recent issue into news-‘cough syrup (Coldbest-PC)’.A quality framework and guidelines process has to be mentioned for recalling any drug which has ill consequences on the larger masses.
This is the fourth mass glycol poisoning event in India that has been caused due to a pharmaceutical drug.
- In 1973, there was a similar incident at the Children’s Hospital, Egmore in Chennai that caused the deaths of 14 children.
- In 1986, similar poisoning at Mumbai’s J.J. Hospital caused the deaths of 14 patients who were otherwise on the path to recovery.
- In 1998, 33 children died in two hospitals located in New Delhi due to similar poisoning.
In all three cases, the manufacturer of the suspect cough syrup, due to negligence or human error, failed to detect and contain the level of diethylene glycol in the syrup, thereby causing poisoning of the patients who consumed it.
TRACKING THE SOLD BOTTLES
There will be plenty of time later to ascertain the cause and prosecute the guilty but the immediate concern for doctors, pharmacists and the drug regulators should be to prevent any more deaths.
The only way to do so is to account for each and every bottle of the poisoned syrup that has ever been sold in the Indian market and stop patients from consuming this drug any further.
Any patient who has consumed even a spoon of the syrup should then immediately be referred to a hospital for treatment.
According to the information available on the website of the United States Food and Drug Administration (USFDA), in 1937, when the United States faced a similar situation with glycol poisoning, its entire field force of 239 inspectors and chemists were assigned to the task of tracking down every single bottle of the drug.
Even if a patient claimed to have thrown out the bottle, the investigators scoured the street until they found the discarded bottle.
This effort was accompanied by a publicity blitz over radio and television.
We do not see such public health measures being undertaken here; authorities are simply not communicating the seriousness of the issue to the general public.
At most, the authorities in Himachal Pradesh (H.P.), who are responsible for oversight of the manufacturer of this syrup, have made general statements that they have ordered the withdrawal of the drug from all the other States where it was marketed.
However, there is no transparency in the recall process and information about recalls and batch numbers is not being communicated through authoritative channels.
There is no public announcement by the Drug Controller General of India (DCGI), which is responsible for overall regulation of the entire Indian market.
The suspect product, although manufactured in H.P., has been sold across the country.
The website of the DCGI, which is supposed to communicate drug alerts and product recalls, has no mention of Coldbest-PC as being dangerous as of this writing.
NEED FOR A RECALL POLICY
One of the key reasons why the DCGI and state drug authorities have been so sloppy is because unlike other countries, India has not notified any binding guidelines or rules on recalling dangerous drugs from the market.
The 59th report of the Parliamentary Standing Committee on Health as well as the World Health Organization (in its national regulatory assessment) had warned the DCGI on the lack of a national recall framework in India.
While a national recall of this adulterated medicine is the immediate need, the administration also needs to quickly identify which other pharmaceutical companies have received the spurious ingredient that was supplied to the manufacturer in H.P. from a trader in Chennai.
It is very likely that the trader in question marketed the same ingredient to other pharmaceutical companies, who, like the manufacturer at the centre of the present scandal, may have failed to test it for its identity and purity.
It is important for regulatory enforcement to raid and seize the records of the trader in Chennai and verify its sales.
As of today, we have little to no information on whether any of this is happening.
The lackadaisical (carelessly lazy) response of drug regulators in India is not surprising.
It is the result of a larger lethargy and arrogance that is emblematic of the babudom(uncountable) which is responsible for keeping us safe from unethical practices of pharmaceutical companies.